Kazuyuki Hamada1,2,3, Yusuke Aoki1,2, Jun Yamamoto1,2, Chihiro Hozumi4, Ming Zhao1, Takuya Murata5, Norihiko Sugisawa1,2, Michael Bouvet2, Takuya Tsunoda6, Robert M Hoffman7,2. 1. AntiCancer Inc, San Diego, CA, U.S.A. 2. Department of Surgery, University of California, San Diego, CA, U.S.A. 3. Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. 4. AntiCancer Japan Inc, Narita, Japan. 5. Department of Obstetrics and Gynecology 2, Kawasaki Medical School, Okayama, Japan. 6. Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; all@anticancer.com ttsunoda@med.showa-u.ac.jp. 7. AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com ttsunoda@med.showa-u.ac.jp.
Abstract
BACKGROUND/AIM: Triple-negative matrix-producing breast carcinoma (MPBC) is rare, recalcitrant, and highly aggressive. The present study aimed to determine the efficacy of tumor-targeting leucine-arginine auxotroph Salmonella typhimurium (S. typhimurium) A1-R on a triple-negative MPBC in a patient-derived orthotopic xenograft (PDOX) model. MATERIALS AND METHODS: The PDOX MPBC model was established in the left second mammary gland of nude mice by surgical orthotopic implantation (SOI). PDOX models were randomized into two groups when the tumor volume reached over 70 mm3: a control group (n=6); and a tumor-targeting S. typhimurium A1-R group (n=7), [intravenous (i.v.) injection of S. typhimurium A1-R via the tail vein, weekly, for two weeks]. All mice were sacrificed on day 14. Tumor volume and body weight were measured once per week. RESULTS: S. typhimurium A1-R exquisitely targeted and arrested the growth of the MPBC PDOX compared to the control group (p=0.017). CONCLUSION: S. typhimurium A1-R has future clinical potential for triple-negative MPBC patients.
BACKGROUND/AIM: Triple-negative matrix-producing breast carcinoma (MPBC) is rare, recalcitrant, and highly aggressive. The present study aimed to determine the efficacy of tumor-targeting leucine-arginine auxotroph Salmonella typhimurium (S. typhimurium) A1-R on a triple-negative MPBC in a patient-derived orthotopic xenograft (PDOX) model. MATERIALS AND METHODS: The PDOX MPBC model was established in the left second mammary gland of nude mice by surgical orthotopic implantation (SOI). PDOX models were randomized into two groups when the tumor volume reached over 70 mm3: a control group (n=6); and a tumor-targeting S. typhimurium A1-R group (n=7), [intravenous (i.v.) injection of S. typhimurium A1-R via the tail vein, weekly, for two weeks]. All mice were sacrificed on day 14. Tumor volume and body weight were measured once per week. RESULTS: S. typhimurium A1-R exquisitely targeted and arrested the growth of the MPBC PDOX compared to the control group (p=0.017). CONCLUSION: S. typhimurium A1-R has future clinical potential for triple-negative MPBC patients.
Authors: Takashi Murakami; Jonathan DeLong; Fritz C Eilber; Ming Zhao; Yong Zhang; Nan Zhang; Arun Singh; Tara Russell; Samantha Deng; Jose Reynoso; Cuong Quan; Yukihiko Hiroshima; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Sant Chawla; Itaru Endo; Robert M Hoffman Journal: Oncotarget Date: 2016-03-15